Purpose Given the potential savings in cost and resource utilization, several algorithms have been proposed to predict Oncotype DX recurrence score (ODX RS) using commonly acquired histopathologic variables. Although it is promising, additional independent validation of these surrogate markers is needed prior to guide the patient management. Methods In this retrospective study, we analyzed 305 patients with invasive breast cancer at our institution who had ODX RS available. We selected five equations that provide a surrogate measure of ODX as previously pub- Results Of all surrogate scores tested, the Magee equation 2 provided the highest correlation with ODX both with regard to raw score (Pearson's correlation coefficient = 0.66 95% CI 0.59-0.72) and categorical correlation (Cohen's kappa = 0.43, 95% CI 0.33-0.53). Although Magee equation 2 provided a way to reliably identify highrisk disease by assigning 95% of the patients with high ODX RS to either the intermediate-or high-risk group, it was unable to reliably identify the potential for patients to have intermediate-or high-risk disease by ODX (66% of such patients identified). Conclusions Although commonly available surrogates for ODX appear to predict high-risk ODX RS, they are unable to reliably rule out the presence of patients with intermediate-risk disease by ODX. Given the potential benefit of adjuvant chemotherapy in women with intermediate-risk disease by ODX, current surrogates are unable to safely substitute for ODX. Characterizing the true recurrence risk in patients with intermediate-risk disease by ODX is critical to the clinical adoption of current surrogate markers and is an area of ongoing clinical trials.
Introduction
The Oncotype DX (ODX) test is a 21-gene expression assay used by oncologists to predict the likelihood of distant recurrence and chemotherapy benefit for patients with breast cancer [1] [2] [3] . Prior to the introduction of ODX, the default management of women with early-stage, hormone receptor-positive disease was adjuvant chemotherapy. However, treatment decisions are now largely guided by the use of ODX, which is recommended by current guidelines for use in women with early-stage, node-negative, hormone receptor-positive, and HER2-negative disease in all but the smallest of tumors (\1 cm) [1] [2] [3] [4] . ODX has been developed as a measure of disease prognosis as the test estimates the 10-year risk of distant recurrence using the ODX recurrence score (RS), which ranges from 0 to 100 and is divided into low-(\18), intermediate- (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , and high-([30) risk disease. A low-risk ODX RS is used to determine which patients have a low risk of distant recurrence when treated only with adjuvant endocrine therapy, and can be spared chemotherapy.
Despite the many benefits of genomic tests including the ODX assay, there are several limitations and draw-backs to the use of such testing including high cost (*$4000), limited availability in resource-poor settings, a several week delay from the time of surgery to test results, and residual uncertainty of management for patients with intermediate RS. The high cost of the assay is thought to be offset via a reduction in chemotherapy attributable costs [5] . Nonetheless, both in limited resource settings as well as in the context of the unsustainable rate of rising costs in cancer care in the US, surrogate estimates of ODX could give potential savings in cost and resource utilization.
Several recent studies have attempted to use standard clinicopathologic markers to create algorithms that provide similar outcome prediction to the ODX assay in an effort to identify patients that can forego having ODX performed while still being provided with reliable information to inform their chemotherapy decisions [6] [7] [8] [9] [10] [11] . These algorithms predict a patient's numerical or categorical ODX RS using routinely acquired histopathologic variables including grade, proliferation indices (Ki-67), receptor status, and tumor size [12] [13] [14] . Although each of the published surrogates involves a different mix of variables and weights, all models predict that stronger estrogen receptor (ER) and progesterone receptor (PR) staining result in lower ODX RS. The remaining factors employed in predicting ODX RS are all established risk factors for recurrence. These teams have developed algorithms able to classify patients into low-and high-risk groups that matched the classifications assigned by their ODX RS. The suggested value of these algorithms is the potential to provide similar information that is provided via the ODX assay while saving costs by using information that is already collected in a treatment context. Such methods would be particularly advantageous for less developed parts of the world where the ODX assay itself may not be readily available to breast cancer patients trying to make decisions as to whether or not to undergo chemotherapy. Although it is promising, a remaining concern regarding these algorithms is the need for extensive validation of these results if they are to be used in place of ODX. Each model uses different specifications based on the developing institution's data, and few studies have attempted to independently confirm their performance in an independent and external patient population. In this study, we lay the groundwork for such a validation by identifying published algorithms being offered as alternatives to ODX and independently assess their ability to predict ODX RS within patients with earlystage, hormone receptor-positive breast cancer at a single large academic institution.
Methods

Patient population
Institutional Review Board approval and waiver of informed consent were secured for this study. We retrospectively searched our institution records for women diagnosed with invasive breast cancer between January 1, 2000 and March 23, 2014. In order to allow verification of histopathologic and clinical factors with genomic risk score, patients were required to have an available ODX RS following diagnosis. Patients were primarily selected on the basis of having received ODX and although ODX was developed in cohorts with node-negative disease our cohort does contain 48 patients with node-positive disease. Patients were also required to have an available preoperative breast MRI without any neoadjuvant therapy or surgery prior to the MRI to help ensure thorough clinical characterization and provide the opportunity to incorporate imaging-based biomarkers in the future.
Data
Patient data were obtained via medical record review and included age, race, menopausal status, TNM staging [15] , type of surgery (breast conservation surgery, mastectomy, no surgery), and neoadjuvant and adjuvant therapy (radiation, chemotherapy, hormone therapy). The data collected from the histopathology reports included the following: ER and PR immunohistochemistry (IHC) (staining percentage, intensity score, Allred score), human epidermal growth factor receptor 2 (HER2) IHC score and FISH (HER2:-CEP17 ratio), Ki-67 index, tumor size, and tumor grading information (Nottingham grade and score, tubule formation, mitotic count, nuclear pleomorphism). In the event that a patient had more than one tumor, clinicopathologic data were used from the same tumor sample on which ODX was performed. If the pathology report assigned a score using a range, the average was used for analysis (i.e., if assigned 95-100% staining, 97.5% was used).
All of the equations used to generate a surrogate score for Oncotype DX are presented in Table 1 . The following provides some details regarding the equations.
Modified Magee equations
Klein et al. [12] described three modified Magee equations based on the original Magee equation [16] . were derived using a method used in Prat et al. [17] and Turner et al. [18] , which modifies the ''H-score'' used in the original Magee equation [16] by multiplying the percent staining from IHC (range 0-100) and the intensity score (0 = none, 1 = weak, 2 = intermediate, 3 = strong) for a range of 0-300 (i.e., 50% staining for ER with a strong staining intensity has a ERIHC of 150) [19] . HER2 status was reported by using IHC according to the College of American Pathologist/American Society of Clinical Oncology (CAP/ASCO) guidelines [20] . Scores of 0 and 1? were considered negative. A score of 3? was considered positive. If the IHC score was 2?, then receptor status was based on the FISH result. A HER2:CEP17 ratio \1.8 was considered negative for HER2, ratio of 1.8-2.2 was equivocal, and ratio [2.2 was positive. The Ki-67 range used was 0-100 [21] . Tumor size was reported in centimeters and collected from the surgical pathology report.
Gage model
The Gage model [13] uses two rules both shown in Table 1 to classify patients into groups likely to either benefit or not benefit from adjuvant chemotherapy. Quantified thresholds of low and high risk for the Gage model were defined by using the TAILORx (Trial Assigning Individualized Options for Treatment (Rx)) trial [22] , which are ODX RS \ 11 and ODX RS [ 25, respectively. Based on these guidelines, chemotherapy would be recommended for patients in the ''high risk'' category and would not be recommended for those that are ''low risk.'' Tumor grade was assigned using the Nottingham grading scale
Tang equation
The Tang equation [14] is shown in Table 1 . In this equation, Allred score (range 0-8) was used for PR. HER2 was either positive (value of 1) or negative (value of 0) using the CAP/ASCO guidelines [20] . If the tumor was of the luminal A molecular subtype a value of 1 was used for ''luminal a'' in the equation, if not then a value of 0. If the tumor was of the luminal B molecular subtype, a value of 1 was used for ''luminal b'' in the equation, if not then a value of 0. Assigning molecular subtype was done by using the ER, PR, and HER2 status of the cancer under the The goal of these analyses was to specifically assess the ability of surrogate endpoints to identify patients in whom a high ODX RS was highly unlikely and ODX testing might be avoided.
As an additional exploratory analysis, we compared the prognostic power of each of the surrogate scores and the ODX RS. We fitted Cox proportional hazards regression models with distant recurrence-free survival as the target outcome to estimate the hazard ratios and Kaplan-Meier curves to visualize the difference in survival characteristics for the patients that were assigned low risk and patients that were assigned intermediate or high risk for all surrogate and ODX recurrence scores. 
Results
A total of 305 women met study criteria and were included for study. The three modified Magee equations, Gage model, and Tang equation were applied to all cases that had the necessary information available. A comparison of the required histopathologic information for each of the algorithms is shown in Table 1 . The clinicopathologic characteristics of cases used for each algorithm are shown in Table 2 . Of all 305 patients with available ODX RS, there were 167 (54.8%) low-risk, 111 (36.4%) intermediate-risk, and 27 (8.8%) high-risk patients using the standard Genomic Health classification cut points. The relationship between the raw ODX RS and surrogate scores as well as the relationship between different surrogate scores are shown in Fig. 1 and Table 3 . Specifically, Table 3 shows the Pearson's correlation coefficients alongside with their confidence intervals as well as the number of cases for analysis of the relationship of each pair of variables. Figure 1 shows the relationship between each pair of variables as a plot as well as a pie chart representation of the correlations. Since the Gage model does not provide a continuous score, it is not represented in Fig. 1 or Table 3 . Table 4 shows the relationship between the ODX RS and surrogate scores represented as one of the three categories: low, intermediate (indeterminate for Gage model), and high. Table 5 shows the relationship between the ODX RS and surrogate score represented as either low risk or non-low risk.
Of all the equations tested, the Magee equation 2 provided the highest correlation with the linear value of true ODX score (0.659). The categorical correlation (Cohen's kappa) between Magee equation 2 and true ODX score was also the highest (0.429) as was the correlation between the score provided by Magee equation 2 and ODX RS when looking at low-risk versus non-low-risk classification (0.463). The correlations between ODX RS and other surrogate scores ranged from 0.446 to 0.556 for linear scores and 0.200 to 0.371 for categorical correlation. Magee equations 1 and 3, both of which involved the use of Ki-67, exhibited the strongest correlation (0.953) with one another ( Fig. 1;  Tables 3, 4) .
Only one patient was incorrectly predicted to have lowrisk disease by surrogates that had high-risk disease by ODX according to the Magee equations 1-3 and the Gage model, while this was true for two of the 22 patients by the Tang equation. Only 1 out of 22 cases with a high RS by ODX had a low RS by Magee 2 and only 1 out of 176 cases with low RS by Magee 2 had a high RS by ODX. Of the 22 patients predicted to have high ODX RS, 10 (45.5%) actually had high-risk disease by Magee equaiton 2. However, it should be noted that only 8.8% of patients in the entire cohort had high ODX RS. Regarding the prognostic power of the surrogate scores and ODX to predict distant recurrence, we observed that there were only five patients in our cohort with a distant recurrence in the observed follow-up period resulting in a very low power of our analysis. correctly assigned all recurrences to the intermediate/high groups, and therefore, there were no events in the low group. This indicates that ODX RS was superior to the surrogate scores for this specific limited sample (it does not imply statistical significance). Kaplan-Meier curves for all recurrence scores are included in the supplemental materials. While none of the hazard ratios were statistically significant, all of the surrogate scores showed some prognostic power for predicting outcomes, demonstrating promise for these approaches. A significant amount of additional data is needed, however, to draw definitive conclusions.
Only one out of the five patients with distant recurrence had each available surrogate score matching the ODX RS. The Magee equation 2 score matched the ODX RS in three out of the five cases. One patient with distant recurrence had each of the five surrogate equations incorrectly predict the disease as low risk when ODX predicted the disease as high risk. This patient had a tumor of 1.2 cm with a Nottingham grade of 1 and Ki-67 of 1%. 
ODX
The upper right hand portion of Table 4 contains confusion tables comparing the number of cases in the L and IH groups between Oncotype algorithms. The lower left hand portion of 
Conclusions and discussion
In this study, we present an independent assessment of currently published clinicopathologic surrogate endpoints for the genomic ODX assay in a population of women with early-stage breast cancer treated at our institution. Of the existing published metrics, in our cohort we observed that the Magee equation 2, which uses a simple weighted combination of ER, PR, HER2, size, and Nottingham score, was able to provide the highest concordance with ODX RS. Because the model relies on ER/PR/HER2, tumor size, and Nottingham score, we found that the data required to calculate this score were available in nearly all patients, as opposed to the Magee equations 1 and 3, which could not be calculated for just over half of patients due to the requirement of Ki-67.
The Magee equation 2 classified 95% of the ODX RS high-risk cases as intermediate or high, suggesting that this surrogate is able to reliably rule out the presence of disease that is considered high risk by ODX. However, it was not able to rule out the presence of intermediate-or high-risk ODX scores grouped together (66%). The inability of any of the examined surrogate histopathologic metrics to accurately determine these intermediate-risk cases raises the question: Where does the additional predictive value of ODX come from? Several of the ODX gene groups could explain this variation including invasion, proliferation, HER-2 status, estrogen receptor status, and a small set of miscellaneous genes. However, since proliferation dominates the ODX equation and Ki-67 is not captured by the Magee equation 2, it seems likely that much of the missed genomic risk score comes from the lack of assessment of proliferation. However, in this study, we showed that metrics that included Ki-67 were in fact inferior in predicting ODX (Magee equations 1 and 3 were inferior to Magee equation 2). Others have previously suggested that the apparent lack of prognostic value from the addition of Ki-67 may be related to interobserver variability, human error, variation in the region assayed, and differences between specific antibodies used for the assay [28, 29] . Therefore, one possible opportunity to improve histopathologic surrogates may lie in improving the standardization of Ki-67 or other proliferation markers [29] . It should also be noted that no assay is perfect, and that some variability in ODX may be related to non-biologic variation. For example, some have suggested that the RT-qPCR assay used by ODX to characterize HER-2 status may not be reliable, with one study citing less than 40% agreement between the ODX classification and the IHC/FISH gold standard [30] . Nonetheless, the ODX assay remains clinically proven to provide accurate prognostication in large prospective studies. Because management of patients with intermediate-risk disease still includes the consideration of chemotherapy, omission of the ODX assay cannot be justified due to the possibility for these patients to benefit from adjuvant chemotherapy. An open question, however, remains as to what is the true risk of recurrence in patients in whom surrogate markers suggest indolent disease, but in whom ODX testing reports intermediate-risk disease. Characterizing the true recurrence risk in this group of patients is critical to the clinical adoption of current surrogate markers. This is the key group of patients whose outcomes might be jeopardized if chemotherapy was omitted based on the use of surrogate markers alone given the potential benefit of adjuvant chemotherapy in these patients. Future areas of research in ongoing trials such as TAILORx [22] and the RxPONDER [31] will help guide the optimal management of patients in whom the ODX RS score reports intermediate-risk disease.
Our study had limitations. First, it was conducted within a single academic medical center. It is possible that there would be systematic difference between the qualities of pathology data between different institutions which would affect precision of the equations examined in this paper. Furthermore, the proportion of patients within our cohort had a lower than usual frequency of ODX high-risk disease and the reliability of the examined surrogates to exclude high-risk disease in other populations may not be as robust as what we observed in our study. Given the relatively few cases of high-risk ODX, the precision of our estimates of false-low-risk disease was limited. Finally, as the cohort available to the investigators for this analysis was those with pre-operative MRIs, some bias might be present due to these selection criteria, which might be expected to represent patients which are higher risk. However, in our cohort, the observed rate of high-risk ODX RS (\10%) was actually lower than the roughly 25% published in other patient populations [1] . This variation in risk score distribution likely reflects the low number of HER2-positive cancers in this cohort, consistent with the limited use of ODX in these cases.
Future work should include repeated validation of the surrogate equations in additional clinical populations, particularly among those with high-risk disease, to confirm the ability of this surrogate to reliably identify patients in whom ODX testing might be safely avoided. An important topic of future work is also comparison of ODX RS with surrogate scores in terms of the outcomes to determine whether discordance in ODX RS and surrogate outcomes results in a decrease in prognostic power of the biomarker. Also of interest is whether the presence of discordance between surrogate models and ODX RS is related to patient outcomes.
